Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 13, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $127.50 to $7,830,617.50.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Chakravarty Ingo, who is SVP, International at GenMark Diagnostics, sold 696 shares at $13.07 on Feb. 13, 2015. Following this transaction, the SVP, International owned 45,843 shares meaning that the stake was reduced by 1.5% with the 696-share transaction.

The shares most recently traded at $13.44, up $0.37, or 2.75% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares sold: 696
  • 12-Week # shares sold: 18,975
  • 24-Week # shares sold: 40,896

The average volume for GenMark Diagnostics has been 160,300 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $563.8 million and is part of the health care sector and health services industry. Shares are down 0.73% year-to-date as of the close of trading on Friday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 3 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CMS Energy (CMS) - FREE Research Report

Butler John M, who is Senior Vice President at CMS Energy, sold 20,000 shares at $35.50 on Feb. 13, 2015. Following this transaction, the Senior Vice President owned 111,119 shares meaning that the stake was reduced by 15.25% with the 20,000-share transaction.

The shares most recently traded at $34.76, down $0.74, or 2.12% since the insider transaction. Historical insider transactions for CMS Energy go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 24,000

The average volume for CMS Energy has been 2.2 million shares per day over the past 30 days. CMS Energy has a market cap of $9.6 billion and is part of the utilities sector and utilities industry. Shares are down 0.29% year-to-date as of the close of trading on Friday.

CMS Energy Corporation operates as an energy company primarily in Michigan, the United States. The stock currently has a dividend yield of 3.35%. The company has a P/E ratio of 19.9. Currently, there are 6 analysts who rate CMS Energy a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMS - FREE

TheStreet Quant Ratings

rates CMS Energy as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

CMS Energy Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Dow Chemical (DOW) - FREE Research Report

Shaw Ruth G, who is Director at Dow Chemical, bought 4,154 shares at $48.19 on Feb. 13, 2015. Following this transaction, the Director owned 32,424 shares meaning that the stake was boosted by 14.69% with the 4,154-share transaction.

The shares most recently traded at $49.16, up $0.97, or 1.97% since the insider transaction. Historical insider transactions for Dow Chemical go as follows:

  • 4-Week # shares bought: 6,228
  • 4-Week # shares sold: 35,000
  • 12-Week # shares bought: 6,228
  • 12-Week # shares sold: 35,000
  • 24-Week # shares bought: 27,728
  • 24-Week # shares sold: 35,000

The average volume for Dow Chemical has been 9.8 million shares per day over the past 30 days. Dow Chemical has a market cap of $58.3 billion and is part of the basic materials sector and chemicals industry. Shares are up 8.4% year-to-date as of the close of trading on Friday.

The Dow Chemical Company manufactures and supplies chemical products for use as raw materials in the manufacture of customer products and services worldwide. The stock currently has a dividend yield of 3.4%. The company has a P/E ratio of 17.2. Currently, there are 6 analysts who rate Dow Chemical a buy, 3 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DOW - FREE

TheStreet Quant Ratings

rates Dow Chemical as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Dow Chemical Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null